Page 2 - Piramal

Piramal Enterprises Q1 results: Net profit down 64% at Rs 181 crore

The retail AUM, which accounts for 72 per cent of the total AUM, increased by 43 per cent Y-o-Y to Rs 50,000 crore

Piramal Enterprises Q1 results: Net profit declines 64% to Rs 181 cr

Piramal Enterprises on Tuesday reported a 64 per cent decline in its June quarter net profit to Rs 181 crore, impacted because of a higher base due to a one-off item last year. The city-headquartered non-bank lender had reported a consolidated net profit of Rs 509 crore in the year-ago period. Its managing director and chief executive Jairam Sridharan said the year-ago performance included a Rs 850 crore benefit from a stake sale in a Shriram Group entity, and added that the performance has been stable in the reporting quarter this year. The core net interest income grew 18 per cent to Rs 807 crore on the back of a 10 per cent increase in the overall assets under management to Rs 70,576 crore, while the net interest margin narrowed to 6.7 per cent from 7.3 per cent in the year-ago period. Sridharan said disbursements were impacted in the June quarter due to regulatory changes around fair practices but exuded confidence that the company will be able to meet its FY25 target of 15 per

Piramal Pharma zooms over 10% on strong Q4 earnings; CDMO biz gives boost

In Q4FY24, Piramal Pharma reported a 102 per cent Year-on-Year (YoY) surge in Profit After Tax (PAT), totaling Rs 101.27 crore

Piramal Pharma Q4 profit Jumps 102% to Rs 101.3 cr, FY24 revenue Up 18%

On a sequential basis, the company's profit jumped more than nine-fold

Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals

The funding will be utilised to improve Biodeal's infrastructure and production capacity

Piramal Enterprises board approves buyback of 14 mn shares at Rs 1,750 cr

Piramal Enterprises on Friday said its board has approved a buyback of 1.4 crore shares at Rs 1,250 each, entailing an outgo of Rs 1,750 crore. The company's board has approved a buyback of up to 1.4 crore shares of face value of Rs 2 each, representing 5.87 per cent of the pre-buyback fully paid-up shares at a price of Rs 1,250 each, aggregating to Rs 1,750 crore through the tender offer route, the Mumbai-based company said in a regulatory filing. The promoter and promoter group shall not participate in the buyback, it added.

Stocks to watch: L&T Tech, Paytm, Rallis India, Piramal Pharma, NMDC

Stocks to watch on July 19, 2023: From Paytm to Piramal Pharma, here are the top stocks to watch in Wednesday's trading session

Piramal Pharma's Rs 1,050 crore rights issue gets Sebi's approval

Proceeds of the issue will be utilised for payment of debt and general corporate purposes

CDPQ divests 0.89% stake in Piramal Pharma via open market transaction

CDPQ on Friday divested a 0.89 per cent stake in Piramal Pharma Ltd for Rs 100 crore through an open market transaction. Caisse De Depot Et Placement Du Quebec (CDPQ) is a global investment group. According to the bulk deal data available with the National Stock Exchange (NSE), CDPQ offloaded a total of 1,05,70,466 shares, amounting to a 0.89 per cent stake in Piramal Pharma. The shares were sold at an average price of Rs 94.48 apiece, taking the transaction size to Rs 99.86 crore. Post the latest transaction, CDPQ's shareholding has been reduced to 4.64 per cent from 5.53 per cent at March-end. Meanwhile, Vanguard Group acquired more than 62 lakh shares of Piramal Pharma at an average price of Rs 94.71 per share, while other buyer(s) identity is not known. Shares of Piramal Pharma went up 3.04 per cent to close at Rs 94.95 per piece on the NSE. In a separate bulk deal, SmallCap World Fund Inc offloaded more than 7 lakh shares of Aavas Financiers for nearly Rs 96 crore through a

Piramal Critical Care appoints US-based Jeffrey Hampton as President, COO

Piramal Critical Care, a part of Piramal Pharma, on Tuesday said it has appointed Jeffrey Hampton as President and Chief Operating Officer (COO). For his new role, Hampton will be based in the United States. He joins the company from Accord Healthcare, where he was President and responsible for accelerating the firm's growth strategy. Before that, he was the Senior Vice President and General Manager at Apotex for the US and Latin America regions. "His experience across the domains of sales and marketing will help us develop stronger, long-term global operations strategies to deliver profitable growth," Piramal Pharma Global Pharma CEO Peter DeYoung said in a statement. His expertise across functions augurs well for the business, as Piramal Critical Care sets its sight to further reinforce its position as a leading global player in complex hospital generics, he added. Piramal Critical Care is a global player in anaesthesia, pain management, and intrathecal therapy. It has a presen

Stocks to Watch: SBI, ICICI Lombard, ONGC, Reliance, Oil India, Zydus Life

Stocks to Watch: ICICI Lombard General Insurance reported a 39.6 per cent surge in net profit in the January-March quarter (Q4) of FY23

Piramal Pharma reports consolidated net loss of Rs 90 crore in Q3

Piramal Pharma on Thursday reported a net loss of Rs 90 crore on a consolidated basis for the third quarter ended December 31, 2022. The Mumbai-based company had reported a net profit of Rs 163 crore in the October-December quarter of last fiscal. Revenue from operations stood at Rs 1,716 crore for the third quarter, while the same was at Rs 1,539 crore in the year-ago period. The company said the third quarter results were not comparable to the same period last year as the NCLT in August 12, 2022 approved the composite scheme of demerger of the pharma business from Piramal Enterprises Ltd (PEL) into Piramal Pharma Ltd. The NCLT also approved amalgamation of Piramal Pharma's wholly-owned subsidiaries Hemmo Pharmaceuticals and Convergence Chemical into itself with an appointed date of April 1, 2022. Accordingly, the financial statements of Piramal Pharma have been prepared giving effect to the scheme from April 1, 2022. "Based on our recent increase in customer engagements and ...

RCap assets' e-auction to kick off on Dec 19; base bid at Rs 5,300 crore

This is the first time that an e-auction of this scale would take place for a debt resolution under the Insolvency and Bankruptcy Code, 2016

Eye on maximum value, lenders say no to Reliance Capital liquidation

"Lenders will decide on the further course of action, including the stance for negotiations on Friday," the source said

RCap liquidation or negotiation? CoC to meet on Tuesday to take a call

While Deloitte, the process advisor to RCap's administrator, is said to be rooting for liquidation, CoC advisor KPMG hopes to close deal and award the firm to highest bidder

Hinduja group, Torrent, Piramal, Oaktree, bid for Reliance Capital

No takers for life and general insurance businesses of the bankrupt company, say sources

Piramal Pharma posts Q2 net loss of Rs 37 cr, revenue grows to Rs 1,720 cr

Piramal Pharma on Wednesday reported a consolidated net loss of Rs 37 crore for the second quarter ended September, as against a net profit of Rs 37 crore in the year-ago period. However, the company's revenue from operations grew to Rs 1,720 crore during the July-September quarter, from Rs 1,578 crore in the corresponding period of the previous fiscal. Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We announce our first results post demerger as an independent and focused pharma company. Over the last 10 years, we have made several strategic choices that have helped nurture and scale our business and establish Piramal Pharma (PPL) as a leading global pharmaceuticals player." "For the quarter and half year ended September 2022, our business has delivered a resilient performance despite multiple internal and external challenges. We expect to deliver a much improved performance in the second half of the current financial year," she added. The National Company Law Tribunal

Tatas to raise Rs 4,000 cr from NHB, bonds market in mega home loan push

Loans to be offered to both retail and developers; funds being raised amid 13% expansion in loan portfolio over six months to September

MSCI sets aside Piramal Pharma's exclusion from global standard index

The company was listed separately on October 19, following its demerger from Piramal Enterprises

Piramal Pharma ends at Rs 192 on debut, valued at Rs 22,882 cr at close

Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock